A sudden personnel shakeup at the FDA has put the agency’s drug review leadership in flux, with Dr. Tracy Beth Høeg saying she was forced out shortly after Dr. Marty Makary’s public exit. This piece lays out who left, who’s stepping in, the quotes at the center of the dispute, and what the switch could mean for policy direction and accountability inside the agency.
Dr. Tracy Beth Høeg, who briefly served as acting director of the FDA’s Center for Drug Evaluation and Research, announced her departure this week and says she was pushed out rather than leaving voluntarily. Her exit came on the heels of former FDA Commissioner Dr. Marty Makary’s public resignation earlier in the week. That rapid turnover has people asking whether the administration is reasserting control and expecting a tighter alignment with its priorities.
TRUMP’S FDA BOSS RESIGNING AS ADMIN TAPS NEXT ACTING LEADER The headlines around Makary’s resignation were loud and immediate, fueled by reports that President Trump was unhappy with how things were being handled at the agency. For Republicans who favor decisive leadership, a swift change in top ranks reads as an effort to bring results and accountability. The optics of the moves are clear: leadership changes signal new direction and closer oversight.
Høeg had been elevated to lead CDER in December after working closely with Makary on drug regulation issues, and she says she did not agree to walk away. “I said I didn’t want to resign,” she told MD Reports. “I said I’m not signing a letter of resignation if it’s not my choice.” Those words landed with a punch because they directly challenge the narrative that these departures were voluntary and routine.
“They made it clear that it wasn’t their decision,” she told the outlet. “They said it was from someone above them, from someone way above their pay grade.” Such direct language raises questions about who ordered the move and why, and it fuels concerns about the independence of career scientists when leadership shifts happen quickly.
TRUMP FDA OVERHAULS COVID-19 VACCINE APPROVAL TO FOCUS ON OLDER POPULATIONS, HIGH-RISK INDIVIDUALS Policy changes reportedly on the table under the new leadership have a clear emphasis: prioritize those most at risk and refine approval criteria. That kind of targeted approach appeals to a conservative view that federal agencies should concentrate on core responsibilities and protect vulnerable Americans first. The debate now is whether the personnel moves will speed policy updates or create short-term disruption inside CDER.
According to internal communication, Høeg will be replaced by her former deputy, Dr. Mike Davis, signaling an internal continuity even as the top team is reworked. An FDA email to staff referenced this transition, and the new acting head will inherit an agency under scrutiny. Leadership swaps at the top of CDER are rare and carry immediate consequences for ongoing reviews and guidance documents.
Other departures are already being reported in tandem with Høeg’s exit, including the former director of the FDA’s Center for Biologics Evaluation and Research, Katherine Szarama, and the agency’s chief of staff, Jim Traficant, according to . Those exits could reshape senior management and create a wider reorganization than a single replacement would suggest. The scale of the turnover makes it harder to predict how quickly the agency will regain steady footing.
The White House has not issued an official comment on the personnel changes, and requests for comment were directed to the FDA, HHS and the individuals involved. For conservative observers, these moves look like a government willing to remove leaders who aren’t aligned with a clear policy agenda. For others, the worry is that rapid staff changes risk undermining institutional expertise during critical regulatory decisions.
What comes next is closely watched: will the new acting leadership accelerate policy shifts, or will internal churn slow crucial reviews and guidance? The names now circulating for senior roles and the tone from the administration suggest a push for tighter oversight and a more targeted focus on high-risk populations in drug and vaccine decisions. The immediate weeks ahead will be the test of whether these personnel changes deliver clearer priorities or simply create more turbulence inside a vital regulatory agency.
https://x.com/matthewherper/status/2055446033165844488
Graduate Student, wife, engaged political and legal writer.